respiratori
virus
common
children
includ
pediatr
recipi
solid
organ
transplant
hematopoiet
stem
cell
transplant
preval
risk
factor
group
review
furthermor
associ
morbid
mortal
pediatr
transplant
recipi
respiratori
viral
infect
address
literatur
specif
prevent
treatment
option
respiratori
syncyti
viru
adenoviru
influenza
respiratori
virus
pediatr
solid
organ
hematopoiet
stem
cell
transplant
recipi
report
respiratori
viral
infect
rvi
children
caus
respiratori
syncyti
viru
rsv
adenoviru
rhinoviru
influenza
viru
parainfluenza
viru
human
metapneumoviru
hmpv
emerg
human
coronavirus
human
bocavirus
although
infect
pathogen
often
result
mild
selflimit
ill
complic
aris
immunocompromis
children
may
experi
signific
morbid
mortal
relat
rvi
compar
otherwis
healthi
counterpart
review
current
literatur
regard
rvi
immunocompromis
childrenspecif
recipi
hematopoiet
stem
cell
transplant
hsct
solid
organ
transplant
sot
order
appreci
signific
pathogen
discuss
method
avail
reduc
rviassoci
morbid
mortal
pediatr
transplant
recipi
respiratori
ill
lead
caus
hospit
children
incid
approxim
furthermor
least
admiss
secondari
rvi
children
present
hospit
acut
respiratori
tract
symptom
antigen
detect
viral
cultur
pcr
identifi
viral
pathogen
mani
episod
common
virus
recov
includ
rsv
rhinoviru
adenoviru
influenza
viru
parainfluenza
viru
enteroviru
hmpv
event
multipl
virus
isol
simultan
discov
hmpv
isol
mani
childhood
lower
respiratori
tract
infect
furthermor
influenza
viru
alon
estim
affect
million
children
age
singl
year
million
calcul
progress
lower
respiratori
tract
infect
studi
rsv
estim
million
children
rsv
requir
medic
attent
year
increas
risk
hospit
prematur
infant
younger
children
summari
rvi
occur
frequent
substanti
impact
child
health
even
immunocompet
popul
rvi
commonli
recogn
pediatr
sot
recipi
decad
longitudin
prospect
surveil
data
popul
current
lack
particularli
nonlung
sot
popul
retrospect
studi
suggest
rvi
common
infecti
episod
pediatr
kidney
liver
transplant
episod
per
patientyear
overal
rhinoviru
report
common
respiratori
viral
pathogen
pediatr
sot
recipi
season
peak
spring
fall
month
similar
commun
pattern
tabl
largest
report
experi
pediatr
lung
transplant
popul
children
experienc
rvi
first
month
follow
transplant
virus
isol
studi
similar
immunocompet
individu
includ
adenoviru
rhinoviru
rsv
parainfluenza
viru
virus
like
progress
lower
respiratori
tract
infect
lrti
rather
remain
limit
upper
respiratori
tract
urti
cohort
younger
patient
receiv
doubl
lung
transplant
increas
risk
rvi
prospect
investig
assess
incid
risk
factor
rvi
pediatr
sot
need
especi
outsid
pediatr
lung
transplant
popul
although
rate
rvi
transplant
patient
compar
otherwis
healthi
peer
risk
rviassoci
complic
may
signific
exampl
liver
transplant
recipi
develop
sever
respiratori
failur
hmpv
immedi
posttranspl
period
colleagu
report
rvi
kidney
liver
transplant
recipi
complic
bacteri
superinfect
includ
acut
otiti
media
sinus
receiv
multipl
cours
antibiot
furthermor
underw
surgic
intervent
recurr
otiti
media
outpac
rate
nontranspl
recipi
lung
transplant
recipi
rvi
directli
affect
graft
complic
frequent
report
publish
studi
date
focus
adult
acut
declin
respiratori
function
increas
risk
acut
reject
rvi
chronic
graft
reject
known
bronchiol
obliteran
syndrom
bo
follow
rvi
report
sever
cohort
howev
date
rvi
found
associ
increas
incid
acut
reject
bo
pediatr
lung
transplant
influenza
particularli
promin
literatur
sinc
pandem
exampl
boy
year
postcardiactranspl
develop
influenza
outbreak
complic
respiratori
failur
requir
extracorpor
membran
oxygen
ecmo
support
day
compar
adult
pediatr
patient
lower
incid
icu
admiss
vs
mechan
ventil
vs
furthermor
pediatr
death
case
compar
adult
interestingli
pediatr
popul
like
adult
receiv
antivir
medic
within
h
symptom
onset
may
affect
outcom
may
reflect
bia
toward
earli
intervent
pediatr
sot
recipi
rvi
symptom
parainfluenza
influenza
adenoviru
report
impact
mortal
older
pediatr
literatur
howev
report
mortal
secondari
rvi
decreas
recent
transplant
era
mortal
influenza
parainfluenza
respect
singlecent
seri
pittsburgh
similarli
pediatr
lung
transplant
recipi
develop
adenoviru
expir
secondari
infect
philadelphia
howev
recent
literatur
show
overal
good
prognosi
rvi
pediatr
sot
liver
kidney
lung
transplant
recipi
overal
mortal
decreas
significantli
studi
focus
impact
rvi
pediatr
sot
recipi
includ
chang
pattern
morbid
mortal
would
benefit
popul
similar
pediatr
sot
pediatr
recipi
hsct
experi
rvi
posttranspl
period
rhinoviru
among
common
pathogen
recov
infect
cohort
tabl
acquisit
viral
infect
occur
equal
frequenc
among
patient
variou
phase
immunolog
recoveri
follow
transplant
neutropen
phase
earli
engraft
phase
late
engraft
phase
signific
proport
hsct
patient
test
posit
singl
respiratori
viru
also
test
posit
copathogen
virus
bacteria
fungi
complic
treatment
strategi
data
suggest
urti
equal
like
lrti
hsct
children
unlik
sot
age
type
organ
transplant
affect
risk
riv
age
sourc
transplant
cell
bone
marrow
peripher
blood
cord
blood
appear
impact
develop
rvi
hsct
recipi
convers
type
transplant
autolog
allogen
may
influenc
risk
rvi
pediatr
allogen
hsct
significantli
associ
symptomat
parainfluenza
viral
infect
compar
autolog
hsct
suggest
hla
compat
develop
chronic
gvhd
may
influenc
one
risk
develop
viral
infect
hsct
although
data
limit
infect
report
cohort
rvi
complic
rvi
hsct
patient
similar
sot
recipi
includ
prolong
hospit
bo
chronic
lung
diseas
ecmo
mechan
ventil
gvhd
death
influenza
pandem
hospit
occur
frequent
hsct
patient
influenza
sever
neutropenia
anc
kul
symptom
rvi
normal
neutrophil
count
although
routin
use
prognost
purpos
high
viral
load
bal
sampl
found
associ
subsequ
mechan
ventil
pediatr
adult
hsct
recipi
quantit
viral
load
bal
sampl
correl
mortal
rather
presenc
serum
viral
rna
put
patient
twofold
increas
risk
mechan
ventil
death
donor
hla
mismatch
although
potenti
associ
initi
infect
link
subsequ
morbid
mortal
pretranspl
condit
howev
impact
clinic
cours
follow
rvi
patient
receiv
total
bodi
irradi
experienc
complic
receiv
chemotherapybas
condit
regimen
appear
complic
rvi
sot
hsct
patient
quit
similar
risk
complic
howev
may
depend
close
protocol
associ
transplant
current
diagnost
tool
allow
identif
viral
etiolog
upper
respiratori
tract
infect
almost
case
collect
nasal
swab
howev
investig
healthi
infant
within
first
year
life
demonstr
viral
isol
asymptomat
children
may
also
occur
nearli
nasopharyng
specimen
thu
identif
highrisk
group
like
benefit
specimen
sampl
continu
essenti
endeavor
diagnost
test
becom
sensit
specif
one
studi
creat
symptom
grade
model
identifi
patient
like
benefit
sampl
author
studi
creat
four
separ
model
util
qualit
measur
common
rvi
symptom
rhinorrhea
cough
fever
other
along
quantit
assess
symptom
durat
assign
sever
score
pediatr
patient
success
model
studi
util
signific
runni
nose
day
signific
cough
day
demonstr
posit
predict
valu
neg
predict
valu
respect
furthermor
younger
children
symptom
qualiti
sever
less
like
elicit
establish
criteria
less
use
util
model
assess
sot
hsct
popul
investig
move
toward
optim
test
protocol
sinc
transplant
patient
particularli
suscept
complic
aris
delay
incomplet
diagnosi
applic
rtpcr
identifi
viral
etiolog
immunocompromis
children
improv
detect
well
expans
virus
detect
compar
convent
rapid
viral
cultur
direct
fluoresc
antigen
viral
culturedfa
multiplex
method
addit
pcr
shown
detect
virus
sampl
fewer
viral
copi
either
convent
method
well
patient
mild
absent
respiratori
symptom
pcr
recent
incorpor
intern
societi
heart
lung
transplant
ishlt
guidelin
diagnos
rvi
cardiothorac
transplant
recipi
becom
wellestablish
tool
identifi
viral
etiolog
step
requir
offici
diagnos
urti
lrti
per
standard
recent
multiplex
platform
test
simultan
multipl
virus
singl
respiratori
sampl
approv
commerci
use
two
platform
filmarray
respiratori
viral
panel
farvp
idaho
technolog
salt
lake
citi
ut
luminex
xtag
respiratori
viral
panel
xtagrvp
luminex
austin
tx
compar
regard
sensit
specif
util
cost
xtagrvp
one
first
fda
approv
multiplex
assay
detect
virus
rsv
b
influenza
untyp
influenza
b
parainfluenza
human
metapneumoviru
adenoviru
enteroviru
farvp
approv
identifi
human
coronavirus
parainfluenza
addit
virus
identifi
xtagrvp
recent
studi
look
respiratori
sampl
pediatr
cancer
patient
determin
farvp
platform
better
abl
identifi
pathogen
nasopharyng
sampl
xtagrvp
platform
moreov
farvp
protocol
faster
xtagrvp
protocol
howev
xtagrvp
found
higher
throughput
better
reliabl
farvp
decis
regard
best
platform
clearli
depend
consider
local
popul
laboratori
volum
develop
futur
platform
ideal
method
sampl
also
come
question
sinc
yield
viral
specimen
may
differ
depend
specimen
sourc
studi
investig
qualiti
nasopharyng
oropharyng
specimen
adult
rvi
demonstr
signific
superior
nasopharyng
wash
nasopharyng
oropharyng
swab
howev
pair
nasopharyng
swab
children
oropharyng
sampl
abl
increas
detect
respiratori
virus
detect
nasopharyng
swab
alon
sampl
lower
airway
often
consid
higher
yield
upper
airway
lower
respiratori
tract
sampl
bronchoalveolar
lavag
acquir
invas
procedur
may
avail
patient
one
third
asymptomat
children
test
posit
viral
infect
studi
examin
bronchoalveolar
lavag
isol
rais
question
whether
result
invas
test
clinic
signific
nevertheless
patient
requir
lower
respiratori
tract
investig
altern
reason
investig
reject
episod
lung
transplant
recipi
evalu
bacteri
fungal
pathogen
lower
tract
sampl
may
warrant
prevent
rvi
pediatr
transplant
patient
critic
tool
minim
infect
associ
complic
vaccin
antivir
prophylaxi
discuss
within
context
specif
virus
howev
prevent
strategi
focus
environment
factor
healthcar
deliveri
system
also
investig
reduc
incid
rvi
precaut
includ
cohort
patient
appli
contact
respiratori
droplet
precaut
assign
specif
healthcar
staff
infect
patient
screen
visitor
infect
prevent
strategi
shown
significantli
decreas
incid
nosocomi
rvi
hsct
patient
subsequ
incorpor
center
diseas
control
prevent
cdc
healthcar
infect
control
practic
advisori
committe
recommend
reduc
healthcareassoci
pneumonia
method
reduc
rvi
hsct
patient
also
specif
address
collabor
guidelin
cdc
infecti
diseas
societi
america
american
societi
blood
marrow
transplant
publish
pediatr
transplant
commun
recogn
import
rvi
prophylaxi
suscept
patient
diminish
associ
morbid
mortal
fda
approv
palivizumab
human
monoclon
antibodi
fusion
protein
rsv
viru
prevent
sever
rsv
infect
highrisk
pediatr
patient
sinc
time
sever
studi
demonstr
efficaci
palivizumab
suppress
acquisit
spread
rsv
immunocompromis
subject
studi
report
current
rsv
prophylaxi
strategi
found
us
pediatr
transplant
center
offer
rsv
prophylaxi
mostli
palivizumab
candid
recipi
sot
palivizumab
often
given
children
age
year
consist
recommend
american
academi
pediatr
true
efficaci
palivizumab
prevent
rviassoci
morbid
transplant
patient
still
debat
one
decis
analysi
model
outcom
pediatr
hsct
patient
given
palivizumab
rsv
prophylaxi
predict
increas
surviv
patient
offer
immunoprophylaxi
howev
anoth
analysi
evalu
use
palivizumab
prevent
rsv
progress
lower
respiratori
tract
diseas
pediatr
adult
allogen
hsct
recipi
conclud
palivizumab
impact
rsvassoci
morbid
mortal
investig
predict
number
need
treat
palivizumab
highrisk
children
due
high
cost
express
concern
offer
palivizumab
prophylaxi
wide
one
studi
estim
would
requir
prevent
one
patient
admiss
secondari
rsv
infect
palivizumab
gener
pediatr
popul
therefor
risk
assess
common
appropri
step
determin
need
rsv
prophylaxi
particular
pediatr
patient
incorpor
current
recommend
american
associ
pediatr
aap
use
palivizumab
rsv
prevent
treatment
rsv
studi
antivir
ribavirin
synthet
nucleosid
analog
fda
approv
treatment
sever
rsv
pneumonia
children
earli
studi
investig
ribavirin
abil
clear
rsv
infect
immunocompromis
patient
promis
howev
patient
identifi
shortli
infect
yet
becom
symptomat
data
like
gener
sinc
pediatr
transplant
center
routin
test
asymptomat
patient
rvi
intervent
delay
symptom
aris
fact
sever
subsequ
studi
suggest
effect
ribavirin
treatment
time
depend
progress
lrti
repres
signific
indic
poor
prognosi
addit
altern
rout
deliveri
includ
oral
intraven
ribavirin
investig
adult
lung
transplant
recipi
report
pediatr
subject
date
due
inconsist
result
ribavirin
especi
children
whose
rsv
infect
extend
lower
respiratori
tract
sever
studi
advoc
concomit
use
immunoglobulin
palivizumab
highrisk
children
palivizumab
shown
decreas
risk
mortal
progress
lower
tract
diseas
least
one
studi
patient
investig
novel
treatment
strategi
warrant
although
adenovir
infect
remain
signific
threat
pediatr
transplant
popul
formal
approv
effect
treatment
option
exist
sever
antivir
replac
therapi
attempt
includ
ribavirin
ganciclovir
vidarabin
cidofovir
intraven
immunoglobulin
leukocyt
transfus
without
definit
success
ribavirin
long
sinc
identifi
effect
clear
sever
viral
infect
includ
adenoviru
vitro
clinic
studi
efficaci
ribavirin
adenoviru
less
convinc
minim
mild
improv
adenovir
infect
intraven
aerosol
smallpopul
clinic
studi
cidofovir
origin
approv
treat
cytomegaloviru
hiv
patient
phosphon
nucleotid
analog
inhibit
viral
dna
polymeras
recent
shown
broadspectrum
antivir
activ
sever
dna
virus
includ
adenoviru
sever
studi
investig
util
cidofovir
pediatr
transplant
recipi
adenoviru
shown
overal
efficaci
safeti
popul
yet
unfavor
toxic
profil
cidofovir
remain
imperfect
treatment
death
report
secondari
dissemin
adenovir
infect
treat
patient
effort
optim
outcom
use
cidofovir
metaanalysi
investig
adenovir
diseas
hsct
patient
suggest
categor
patient
level
risk
use
method
dose
mgkgday
mgkgweek
propos
viral
load
drop
copi
per
millilit
least
two
consecut
sampl
case
seri
pediatr
lung
transplant
addit
report
success
treatment
adenoviru
infect
lowdos
cidofovir
mgkgdose
everi
day
conjunct
probenicid
hydrat
intraven
immunoglobulin
vaccin
remain
public
health
sector
primari
effort
prevent
acquisit
transmiss
influenza
season
influenza
vaccin
cover
predict
widespread
strain
influenza
influenza
b
subtyp
influenza
season
antigen
character
allow
specif
strain
identif
incorpor
follow
year
prepar
rout
administr
season
influenza
vaccin
includ
intramuscular
intraderm
intranas
pediatr
popul
two
prepar
avail
unit
state
trival
inactiv
intramuscular
vaccin
month
age
older
live
attenu
intranas
vaccin
year
age
older
live
attenu
vaccin
recommend
posttranspl
recipi
howev
may
use
close
contact
transplant
recipi
inactiv
viru
avail
protect
influenza
infect
follow
vaccin
occur
via
antibodi
cellmedi
immun
respons
although
studi
pediatr
transplant
recipi
demonstr
gener
adequ
antibodi
respons
influenza
vaccin
popul
cellmedi
respons
may
suboptim
find
like
relat
immunosuppress
regimen
transplant
recipi
aim
minim
tcellmedi
graft
dysfunct
detail
immunosuppress
vaccin
protocol
also
investig
attempt
optim
vaccin
respons
instanc
steroidspar
agent
appear
offer
advantag
steroidcontain
agent
term
magnitud
antibodi
respons
influenza
vaccin
demonstr
studi
pediatr
kidney
transplant
recipi
furthermor
addit
booster
dose
influenza
vaccin
shown
increas
serolog
convers
rate
pediatr
kidney
liver
transplant
recipi
vaccin
influenza
strongli
suggest
famili
member
close
contact
includ
healthcar
worker
sot
hsct
recipi
creat
circl
protect
around
immunocompromis
host
pandem
influenza
vaccin
receiv
particular
attent
vaccin
strain
shown
offer
protect
pediatr
transplant
recipi
without
signific
advers
effect
serolog
convers
rate
may
lower
follow
vaccin
pediatr
transplant
recipi
healthi
control
howev
administr
coordin
season
influenza
vaccin
allow
bolster
immun
respons
popul
contrari
season
influenza
vaccin
addit
booster
dose
vaccin
shown
increas
seroconvers
rate
group
pediatr
liver
transplant
recipi
howev
ast
guidelin
recommend
booster
vaccin
sinc
data
still
limit
asid
vaccin
prevent
influenza
suggest
use
prophylact
antivir
oseltamivir
potent
neuraminidas
inhibitor
use
treat
influenza
studi
prophylact
agent
pediatr
cancer
patient
case
influenza
note
popul
offer
oseltamivir
prophylaxi
minor
side
effect
report
recent
studi
compar
oseltamivir
prophylaxi
placebo
cohort
mostli
adult
sot
hsct
recipi
report
signific
decreas
laboratoryconfirm
influenza
determin
revers
transcriptasepcr
studi
period
oseltamivir
prophylaxi
vs
placebo
oseltamivir
resist
immunocompromis
popul
surfac
remind
clinician
choic
prophylact
antivir
determin
basi
properti
current
circul
influenza
viru
amantadin
anoth
antivir
interfer
viral
uncoat
util
less
due
resist
note
season
recommend
regard
appropri
prophylact
agent
revis
publish
yearli
cdc
collabor
laboratori
base
current
resist
pattern
circul
influenza
strain
pandem
novel
influenza
strain
creat
resurg
literatur
evalu
antivir
treatment
option
highrisk
patient
oral
neuraminidas
inhibitor
oseltamivir
indic
treatment
uncompl
influenza
b
infect
children
year
older
symptomat
h
dose
rang
mg
twice
day
base
weight
primari
goal
treatment
influenza
transplant
patient
offer
antivir
treatment
soon
possibl
initi
present
oseltamivir
shown
significantli
reduc
hospit
stay
critic
ill
children
infect
season
influenza
sot
recipi
pandem
influenza
demonstr
lower
icu
admiss
rate
patient
offer
oseltamivir
within
h
symptom
onset
zanamivir
inhal
neurominidas
inhibitor
less
frequent
util
may
offer
altern
treatment
unrespons
oseltamivir
indic
similar
oseltamivir
except
recommend
children
year
older
dose
mg
twice
daili
day
deliv
via
oral
inhal
disk
peramivir
neurominidas
inhibitor
grant
emerg
use
author
feder
drug
associ
treatment
influenza
infect
hospit
adult
pediatr
patient
requir
iv
therapi
follow
failur
oral
inhal
antivir
medic
first
intraven
antivir
medic
avail
treatment
influenza
although
intraven
formul
oseltamivir
zanamivir
investig
clinicaltrialsgov
peramivir
licens
japan
south
korea
found
effect
suscept
influenza
b
virus
phase
clinic
trial
current
underway
examin
effect
ad
peramivir
institut
standard
care
improv
symptom
nasopharyng
viral
load
adult
adolesc
hospit
influenza
infect
clinicaltrialsgov
preliminari
studi
conduct
japan
demonstr
improv
symptom
reduct
viral
load
pediatr
patient
given
mgkgday
peramivir
infus
influenza
infect
studi
transplant
patient
yet
report
despit
avail
sever
antivir
medic
treatment
influenza
current
manag
strategi
focu
prevent
infect
suscept
host
vaccin
sinc
complic
aris
infect
quit
sever
treatment
respiratori
virus
includ
parainfluenza
viru
human
metapneumoviru
report
literatur
howev
gener
case
report
random
clinic
trial
gaug
efficaci
antivir
intervent
ribavirin
report
potenti
strategi
treat
parainfluenza
viru
human
metapneumoviru
context
case
report
seri
adult
sot
pediatr
hsct
recipi
although
success
respons
consist
howev
support
therapi
without
antivir
also
success
report
evalu
potenti
treatment
strategi
common
respiratori
viral
pathogen
warrant
respiratori
viral
infect
affect
pediatr
recipi
sot
hsct
preval
appear
similar
children
howev
increas
risk
morbid
mortal
influenc
caregiv
vigil
detect
rvi
children
prevent
essenti
includ
vaccin
influenza
investig
treatment
modal
need
expand
treatment
option
disclosur
potenti
conflict
interest
relev
articl
report
